LIG1 and neoplasm: Consistent with our previous results in 22Rv1, the administration of PARPi significantly decreased LIG1-KO cell proliferation in all tumor models, indicating that this SL interaction is conserved in different tumor types (corrected P values for sgLIG1 [1] and [2] treated with PARPi <0.05) (Figure 5, B and C, and Supplemental Figure 5, B and C).